The 2025 Plenary Meeting of the PROMS Initiative highlighted a major shift in the future of multiple sclerosis research and care: Patient-Reported Outcome Measures (PROMs) are evolving from simple clinical trial endpoints into key drivers of therapeutic innovation.
Bringing together researchers, clinicians, regulators, patient advocates and industry representatives, the plenary explored how patient experience is increasingly shaping regulatory science, biological understanding and therapy development in MS.
Across all three sessions, one message clearly emerged: the future of MS care must be built around evidence that reflects the real experiences of people living with the disease. While traditional measures such as MRI activity and disability progression remain important, speakers stressed that they often fail to capture symptoms and challenges that deeply affect patients’ daily lives, including fatigue, cognition, pain and quality of life.
Participants also discussed the growing importance of PROMs within regulatory frameworks and drug development processes. However, the plenary strongly emphasised that regulatory qualification alone is not enough. Clinical relevance and meaningful dialogue between healthcare professionals and patients must evolve alongside scientific and regulatory progress.
The discussions reflected a broader transformation taking place across the MS community, where patient experience is becoming an essential part of evidence generation rather than a secondary consideration.
Ultimately, the PROMS 2025 Plenary reinforced a shared vision for the future: a more patient-centred approach to innovation, where PROMs not only improve science and accelerate therapy development, but also contribute to better and more meaningful care for people living with multiple sclerosis.
Watch the full plenary: here